AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24915066 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupoint acupuncture for 8 weeks
Number of subjects: 80
Study 24915066 — intervention group
Group type: COMPARATOR
Intervention: Inactive acupoint acupuncture for 8 weeks
Number of subjects: 80
Study 24915066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Active and Inactive acupoint)
Number of subjects: 80
Study 24915066 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupoint group
Number of subjects: 80
Study 23259263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Yuji (LU 10), needle inserted 20-35 mm in depth, retained for 60 min, rotated every 5 min
Number of subjects: 577
Study 23259263 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol aerosol, 200 microg, less than 8 sprays in 24 h
Number of subjects: 577
Study 20009958 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment plus self-care
Number of subjects: 267
Study 20009958 — intervention group
Group type: COMPARATOR
Intervention: Self-care alone (Control)
Number of subjects: 267
Study 18486419 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 87
Study 18486419 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 87
Study 16682850 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimic Investigatory Test, Edinburgh (BITE)
Number of subjects: 995
Study 16682850 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Scale of BITE
Number of subjects: 995
Study 12775312 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate infusion
Number of subjects: 19
Study 12775312 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 19
Study 10503800 — intervention group
Group type: EXPERIMENTAL
Intervention: Data monitoring committee with formal analyses every 6 months
Number of subjects: 0
Study 10503800 — intervention group
Group type: EXPERIMENTAL
Intervention: Common statistical monitoring guidelines
Number of subjects: 0
Study 8921129 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 86
Study 8921129 — intervention group
Group type: COMPARATOR
Intervention: D&C (Dilatation and curettage)
Number of subjects: 86
Study 1841669 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 0
Study 1841669 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanolol 80 mg
Number of subjects: 0
Study 1841669 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg
Number of subjects: 0
Study 1841669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31584525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional ozone gas
Number of subjects: 74
Study 31584525 — intervention group
Group type: COMPARATOR
Intervention: Intralesional saline injection
Number of subjects: 74
Study 29454336 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in physical activity level (measured by the self-report Physical Activity Scale for the Elderly (PASE))
Number of subjects: 514
Study 26328787 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine + Vecuronium
Number of subjects: 22
Study 26328787 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22
Study 26328787 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 24849043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual testosterone (0.5 mg) followed by buspirone (10 mg) tablet
Number of subjects: 13
Study 24849043 — intervention group
Group type: COMPARATOR
Intervention: Combination tablet of testosterone and buspirone
Number of subjects: 13
Study 23110701 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior preperitoneal approach (Group A)
Number of subjects: 120
Study 23110701 — intervention group
Group type: COMPARATOR
Intervention: Conventional anterior tension‐free repair (Group B)
Number of subjects: 120
Study 20209619 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 1813
Study 20209619 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1813
Study 18611975 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 10
Study 18611975 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 10
Study 16967791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Artery Catheter (PAC)
Number of subjects: 0
Study 16967791 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 14597456 — intervention group
Group type: EXPERIMENTAL
Intervention: Leech therapy (4 to 6 locally applied leeches)
Number of subjects: 51
Study 14597456 — intervention group
Group type: COMPARATOR
Intervention: Topical diclofenac therapy (28-day regimen)
Number of subjects: 51
Study 14597456 — intervention group
Group type: EXPERIMENTAL
Intervention: Leech therapy
Number of subjects: 51
Study 10748449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretherapeutic hyperprolactinemia (PRL >/=15.0 ng/mL)
Number of subjects: 99
Study 10748449 — intervention group
Group type: COMPARATOR
Intervention: Pretherapeutic PRL levels
Number of subjects: 99
Study 10748449 — intervention group
Group type: EXPERIMENTAL
Intervention: PRL mRNA expression
Number of subjects: 99
Study 10748449 — intervention group
Group type: EXPERIMENTAL
Intervention: PRLR positivity by ligand binding assay
Number of subjects: 99
Study 10748449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate form of PRLR mRNA
Number of subjects: 99
Study 10748449 — intervention group
Group type: EXPERIMENTAL
Intervention: Long form of PRLR mRNA
Number of subjects: 99
Study 9026624 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to dusts and solvent vapours
Number of subjects: 146
Study 9026624 — intervention group
Group type: EXPERIMENTAL
Intervention: Short period of employment
Number of subjects: 146
Study 9026624 — intervention group
Group type: EXPERIMENTAL
Intervention: Long period of employment
Number of subjects: 146
Study 9026624 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of exposure
Number of subjects: 146
Study 9026624 — intervention group
Group type: EXPERIMENTAL
Intervention: First period of exposure
Number of subjects: 146
Study 9026624 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer period of exposure
Number of subjects: 146
Study 1551541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin supplementation
Number of subjects: 15
Study 1551541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3891189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 gm)
Number of subjects: 10
Study 3891189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide gel (30 ml)
Number of subjects: 10
Study 3891189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31050156 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-lowering intervention
Number of subjects: 6826
Study 31050156 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering intervention
Number of subjects: 6826
Study 31050156 — intervention group
Group type: COMPARATOR
Intervention: Low 1,5-AG level (<39.7 μmol/L)
Number of subjects: 6826
Study 31050156 — intervention group
Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 6826
Study 29342453 — intervention group
Group type: EXPERIMENTAL
Intervention: True air purifiers
Number of subjects: 55
Study 29342453 — intervention group
Group type: COMPARATOR
Intervention: Sham air purifiers
Number of subjects: 55
Study 26614591 — intervention group
Group type: COMPARATOR
Intervention: Sporting Qigong (SQG)
Number of subjects: 95
Study 26614591 — intervention group
Group type: COMPARATOR
Intervention: Non-Sporting Qigong (NSQG)
Number of subjects: 95
Study 26614591 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study 24155118 — intervention group
Group type: EXPERIMENTAL
Intervention: Back Squat
Number of subjects: 13
Study 24155118 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Clean
Number of subjects: 13
Study 24155118 — intervention group
Group type: COMPARATOR
Intervention: Control Condition
Number of subjects: 13
Study 22819848 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 32
Study 22819848 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy control group
Number of subjects: 32
Study 21171757 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin depletion
Number of subjects: 0
Study 21171757 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18442449 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 110 microg once daily
Number of subjects: 302
Study 18442449 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 302
Study 16186434 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg DRSP/1 mg E2
Number of subjects: 213
Study 16186434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 12013355 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 4.0 g-tazobactam 0.5 g administered every 8 hours
Number of subjects: 12
Study 12013355 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 3.0 g-tazobactam 0.375 g administered every 6 hours
Number of subjects: 12
Study 12013355 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin 3.0 g-tazobactam 0.375 g every 4 hours
Number of subjects: 12
Study 12013355 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin 4.0 g-tazobactam 0.5 g every 6 hours
Number of subjects: 12
Study 12013355 — intervention group
Group type: COMPARATOR
Intervention: Continuous-infusion piperacillin 12 g-tazobactam 1.5 g/day
Number of subjects: 12
Study 10202313 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 6 microm monodisperse Teflon particles labelled with 111In after bronchial provocation with allergen
Number of subjects: 9
Study 10202313 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of 6 microm monodisperse Teflon particles labelled with 111In (control measurement)
Number of subjects: 9
Study 8636519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation at six different values of expiratory time (TE) with constant tidal volume and total breath duration
Number of subjects: 9
Study 8636519 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of end-inspiratory pause (EIP)
Number of subjects: 9
Study 2281671 — intervention group
Group type: EXPERIMENTAL
Intervention: anxiolytic drug
Number of subjects: 60
Study 2281671 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 444024 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief hospitalization followed by the availability of transitional day care
Number of subjects: 175
Study 444024 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief hospitalization
Number of subjects: 175
Study 444024 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient care
Number of subjects: 175
Study 31109349 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 100
Study 31109349 — intervention group
Group type: COMPARATOR
Intervention: Exposure and response prevention (ERP)
Number of subjects: 100
Study 28074798 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 200
Study 28074798 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 200
Study 26156269 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic administration with vibration
Number of subjects: 30
Study 26156269 — intervention group
Group type: COMPARATOR
Intervention: Injections without the use of vibration
Number of subjects: 30
Study 22484576 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (3 courses of fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2)) followed by DOC (3 courses of docetaxel 100 mg/m(2))
Number of subjects: 42
Study 22484576 — intervention group
Group type: EXPERIMENTAL
Intervention: DOC (3 courses of docetaxel 100 mg/m(2)) followed by FEC (3 courses of fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2))
Number of subjects: 42
Study 21852678 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring (BGM)
Number of subjects: 72
Study 19436696 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 137
Study 19436696 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate
Number of subjects: 137
Study 16923097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg, Midazolam 0.03 mg/kg, Propofol 2.5 mg/kg (group FMP)
Number of subjects: 80
Study 16923097 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 microg/kg, Lignocaine 1.5 mg/kg, Propofol 2.5 mg/kg (group FLP)
Number of subjects: 80
Study 12784100 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg q.d.
Number of subjects: 12
Study 12784100 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg b.i.d.
Number of subjects: 12
Study 12784100 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimens of Duloxetine
Number of subjects: 12
Study 12784100 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine 50 mg b.i.d.
Number of subjects: 12
Study 12784100 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine and Desipramine
Number of subjects: 12
Study 12784100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10864586 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (3 mg/kg priming dose + 3 mg/kg per h)
Number of subjects: 7
Study 10864586 — intervention group
Group type: EXPERIMENTAL
Intervention: HOI superimposed on L‐NMMA infusion
Number of subjects: 7
Study 10864586 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (time control)
Number of subjects: 7
Study 10864586 — intervention group
Group type: COMPARATOR
Intervention: HOI without L‐NMMA infusion
Number of subjects: 7
Study 10864586 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA
Number of subjects: 7
Study 8875556 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol acetate (125 mg/g) applied twice daily for three months
Number of subjects: 19
Study 8875556 — intervention group
Group type: COMPARATOR
Intervention: difluoromethylornithine cream applied twice daily for three months
Number of subjects: 19
Study 1843365 — intervention group
Group type: EXPERIMENTAL
Intervention: Quassia Amarga (alcoholic solution)
Number of subjects: 148
Study 1843365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 6470621 — intervention group
Group type: EXPERIMENTAL
Intervention: human‐film aggression
Number of subjects: 96
Study 6470621 — intervention group
Group type: EXPERIMENTAL
Intervention: cartoon‐film aggression
Number of subjects: 96
Study 6470621 — intervention group
Group type: COMPARATOR
Intervention: neutral film
Number of subjects: 96
Study 6470621 — intervention group
Group type: EXPERIMENTAL
Intervention: real‐life (act of war) aggression
Number of subjects: 96
Study 30797257 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2) dentifrice (Colgate TotalSF) stabilized with zinc phosphate
Number of subjects: 100
Study 30797257 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride control dentifrice
Number of subjects: 100
Study 29518094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin lispro infusion (CSII)
Number of subjects: 24
Study 29518094 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 24
Study 29518094 — intervention group
Group type: COMPARATOR
Intervention: Once-daily insulin isophane
Number of subjects: 24
Study 26682871 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy in the low-risk group (GH >67)
Number of subjects: 451
Study 26682871 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy in the intermediate-risk group (46 ≤ GH ≤ 67)
Number of subjects: 451
Study 26682871 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy in the high-risk group (GH <46)
Number of subjects: 451
Study 26682871 — intervention group
Group type: EXPERIMENTAL
Intervention: Global health status (GH) score at baseline
Number of subjects: 451
Study 24456362 — intervention group
Group type: EXPERIMENTAL
Intervention: Doenjang (9.8 g/day)
Number of subjects: 60
Study 24456362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22621409 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education group
Number of subjects: 42
Study 20698962 — intervention group
Group type: EXPERIMENTAL
Intervention: Kopstoring intervention (online intervention for COPMI-children)
Number of subjects: 214
Study 20698962 — intervention group
Group type: COMPARATOR
Intervention: Waiting list care as usual (control group)
Number of subjects: 214
Study 20698962 — intervention group
Group type: EXPERIMENTAL
Intervention: Kopstoring intervention (extended measure at 12 months)
Number of subjects: 214
Study 17931765 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 48
Study 17931765 — intervention group
Group type: COMPARATOR
Intervention: Single Bond
Number of subjects: 48
Study 17931765 — intervention group
Group type: COMPARATOR
Intervention: Clearfil Tri S Bond
Number of subjects: 48
Study 15775733 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) 0.625 mg conjugated equine estrogens (CEE) combined with 2.5 mg medroxyprogesterone
Number of subjects: 16
Study 15775733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HRT and Simvastatin (20 mg)
Number of subjects: 16
Study 15775733 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (20 mg)
Number of subjects: 16
Study 15775733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11934159 — intervention group
Group type: EXPERIMENTAL
Intervention: Local motion detectors
Number of subjects: 0
Study 11934159 — intervention group
Group type: EXPERIMENTAL
Intervention: Global motion detectors
Number of subjects: 0
Study 10559578 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% budesonide in Finn Chambers
Number of subjects: 10
Study 10559578 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide‐printed polyester squares in serial doses (150‐0.074 microg/cm(2))
Number of subjects: 10
Study 10559578 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubtful or weakly visible reactivity at the test edges assessed by test perfusion assessments
Number of subjects: 10
Study 7586263 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-cc can size
Number of subjects: 24
Study 7586263 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-cc can size
Number of subjects: 24
Study 7586263 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-cc can size
Number of subjects: 24
Study 2122037 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral branched-chain amino acids (BCAA)
Number of subjects: 0
Study 2122037 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA
Number of subjects: 0
Study 204248 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% solution of prodigiosan administered intranasally (0.2 ml once every 4 days for 4 months)
Number of subjects: 0
Study 31136233 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium
Number of subjects: 30
Study 31136233 — intervention group
Group type: COMPARATOR
Intervention: Blue Dye
Number of subjects: 30
Study 31136233 — intervention group
Group type: COMPARATOR
Intervention: Green Dye
Number of subjects: 30
Study 27859471 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 17
Study 27859471 — intervention group
Group type: COMPARATOR
Intervention: No soft tissue grafting (control)
Number of subjects: 17
Study 25095746 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating TNF‐α
Number of subjects: 75
Study 25095746 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating CRP
Number of subjects: 75
Study 25095746 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating sICAM
Number of subjects: 75
Study 25095746 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating IL‐6
Number of subjects: 75
Study 25095746 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression of IL‐6
Number of subjects: 75
Study 25095746 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression of CD36
Number of subjects: 75
Study 25095746 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression of TNF‐α
Number of subjects: 75
Study 23587440 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning
Number of subjects: 0
Study 23587440 — intervention group
Group type: COMPARATOR
Intervention: Losing
Number of subjects: 0
Study 21422866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal pH-balanced gel (administered three times per week for 12 weeks)
Number of subjects: 86
Study 21422866 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered three times per week for 12 weeks)
Number of subjects: 86
Study 19363969 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 15-minute in-office bleaching treatments with 36% hydrogen peroxide followed by at-home overnight bleaching with 15% carbamide peroxide for seven days.
Number of subjects: 37
Study 19363969 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-minute in-office bleaching treatment followed by at-home overnight bleaching for seven days.
Number of subjects: 37
Study 19363969 — intervention group
Group type: COMPARATOR
Intervention: In-office treatment without at-home bleaching.
Number of subjects: 37
Study 17466675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin injection
Number of subjects: 35
Study 17466675 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 35
Study 15226561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime 5 mg/kg b.i.d. for 10-14 days
Number of subjects: 776
Study 15226561 — intervention group
Group type: COMPARATOR
Intervention: Cefixime 4 mg/kg b.i.d. for 10-14 days
Number of subjects: 776
Study 11489703 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 5335
Study 9333320 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7971430 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom management interventions
Number of subjects: 28